SG10202111808WA - 5-bromo-2,6-di-(1h-pyrazol-1-yl)pyrimidin-4-amine for use in the treatment of cancer - Google Patents
5-bromo-2,6-di-(1h-pyrazol-1-yl)pyrimidin-4-amine for use in the treatment of cancerInfo
- Publication number
- SG10202111808WA SG10202111808WA SG10202111808WA SG10202111808WA SG10202111808WA SG 10202111808W A SG10202111808W A SG 10202111808WA SG 10202111808W A SG10202111808W A SG 10202111808WA SG 10202111808W A SG10202111808W A SG 10202111808WA SG 10202111808W A SG10202111808W A SG 10202111808WA
- Authority
- SG
- Singapore
- Prior art keywords
- pyrazol
- pyrimidin
- bromo
- cancer
- amine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15382425 | 2015-08-11 | ||
| US201662335984P | 2016-05-13 | 2016-05-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10202111808WA true SG10202111808WA (en) | 2021-11-29 |
Family
ID=53887054
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202111808WA SG10202111808WA (en) | 2015-08-11 | 2016-08-10 | 5-bromo-2,6-di-(1h-pyrazol-1-yl)pyrimidin-4-amine for use in the treatment of cancer |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US10561653B2 (fr) |
| EP (1) | EP3334431B9 (fr) |
| JP (1) | JP6663493B2 (fr) |
| KR (1) | KR102114562B1 (fr) |
| CN (2) | CN108348521B (fr) |
| AU (1) | AU2016306090B2 (fr) |
| BR (1) | BR112018002585A2 (fr) |
| CA (1) | CA2994918C (fr) |
| CY (1) | CY1122966T1 (fr) |
| MX (1) | MX2018001721A (fr) |
| PH (1) | PH12018500284A1 (fr) |
| PL (1) | PL3334431T3 (fr) |
| RS (1) | RS59688B1 (fr) |
| SA (1) | SA518390901B1 (fr) |
| SG (1) | SG10202111808WA (fr) |
| SI (1) | SI3334431T1 (fr) |
| WO (1) | WO2017025918A1 (fr) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20200094A1 (ar) * | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
| ES2771926T3 (es) | 2014-09-13 | 2020-07-07 | Novartis Ag | Terapias de combinación |
| SG10202111808WA (en) * | 2015-08-11 | 2021-11-29 | Novartis Ag | 5-bromo-2,6-di-(1h-pyrazol-1-yl)pyrimidin-4-amine for use in the treatment of cancer |
| AU2016354688B2 (en) | 2015-11-09 | 2021-12-16 | The University Of British Columbia | Epitopes in Amyloid beta mid-region and conformationally-selective antibodies thereto |
| CA3058492A1 (fr) | 2016-04-06 | 2017-10-12 | Noxopharm Limited | Ameliorations de la radiotherapie |
| AU2017247008B2 (en) | 2016-04-06 | 2022-04-07 | Noxopharm Limited | Isoflavonoid composition with improved pharmacokinetics |
| CN116333108A (zh) | 2016-07-18 | 2023-06-27 | 英属哥伦比亚大学 | 淀粉样蛋白β的抗体 |
| US10899844B2 (en) | 2017-02-08 | 2021-01-26 | Novartis Ag | FGF21 mimetic antibodies and uses thereof |
| CN110290808B (zh) | 2017-02-10 | 2023-07-11 | 诺华股份有限公司 | 1-(4-氨基-5-溴-6-(1h-吡唑-1-基)嘧啶-2-基)-1h-吡唑-4-醇及其在治疗癌症中的用途 |
| JOP20190279A1 (ar) | 2017-05-31 | 2019-11-28 | Novartis Ag | الصور البلورية من 5-برومو -2، 6-داي (1h-بيرازول -1-يل) بيريميدين -4- أمين وأملاح جديدة |
| US11312783B2 (en) | 2017-06-22 | 2022-04-26 | Novartis Ag | Antibody molecules to CD73 and uses thereof |
| US20200172628A1 (en) | 2017-06-22 | 2020-06-04 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
| SG11202000431PA (en) | 2017-07-18 | 2020-02-27 | Nuvation Bio Inc | 1,8-naphthyridinone compounds and uses thereof |
| WO2019018584A1 (fr) | 2017-07-18 | 2019-01-24 | GiraFpharma LLC | Composés hétérocycliques utilisés en tant qu'antagonistes de l'adénosine |
| JP7330164B2 (ja) * | 2017-07-18 | 2023-08-21 | ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア | アミロイドベータに対する抗体 |
| CA3081602A1 (fr) | 2017-11-16 | 2019-05-23 | Novartis Ag | Polytherapies |
| JP2021509009A (ja) | 2017-11-30 | 2021-03-18 | ノバルティス アーゲー | Ｂｃｍａターゲティングキメラ抗原受容体及びその使用 |
| CA3090922A1 (fr) * | 2018-02-16 | 2019-08-22 | Arcus Biosciences, Inc. | Dosage avec un compose azolopyrimidine |
| SG11202008390SA (en) | 2018-03-14 | 2020-09-29 | Surface Oncology Inc | Antibodies that bind cd39 and uses thereof |
| KR102183677B1 (ko) | 2018-04-26 | 2020-11-27 | 주식회사 엘지화학 | 광학 디바이스 및 이의 용도 |
| AR126019A1 (es) | 2018-05-30 | 2023-09-06 | Novartis Ag | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación |
| WO2019232244A2 (fr) | 2018-05-31 | 2019-12-05 | Novartis Ag | Molécules d'anticorps anti-cd73 et leurs utilisations |
| UY38251A (es) | 2018-06-01 | 2019-12-31 | Novartis Ag | Moléculas de unión contra bcma y usos de las mismas |
| CN112533923B (zh) | 2018-06-04 | 2024-07-09 | 爱克思科技有限公司 | 作为腺苷受体拮抗剂的吡唑并嘧啶化合物 |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| US20240245670A1 (en) | 2018-12-20 | 2024-07-25 | Novartis Ag | Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
| CN113924095A (zh) | 2019-01-18 | 2022-01-11 | 诺维逊生物股份有限公司 | 作为腺苷拮抗剂的杂环化合物 |
| EP3911324A4 (fr) | 2019-01-18 | 2022-08-17 | Nuvation Bio Inc. | Composés de 1,8-naphthyridinone et leurs utilisations |
| EP3924054A1 (fr) | 2019-02-15 | 2021-12-22 | Novartis AG | Dérivés de 3-(1-oxo-5-(pipéridin-4-yl)isoindolin-2-yl)pipéridine-2,6-dione et leurs utilisations |
| BR112021015672A2 (pt) | 2019-02-15 | 2021-10-05 | Novartis Ag | Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona substituída e usos dos mesmos |
| WO2021055329A1 (fr) | 2019-09-16 | 2021-03-25 | Surface Oncology, Inc. | Compositions d'anticorps anti-cd39 et procédés associés |
| TW202124446A (zh) | 2019-09-18 | 2021-07-01 | 瑞士商諾華公司 | 與ｅｎｔｐｄ２抗體之組合療法 |
| WO2021053559A1 (fr) | 2019-09-18 | 2021-03-25 | Novartis Ag | Anticorps d'entpd2, polythérapies, et procédés d'utilisation des anticorps et des polythérapies |
| TW202128752A (zh) | 2019-09-25 | 2021-08-01 | 美商表面腫瘤學公司 | 抗ｉｌ﹘２７抗體及其用途 |
| WO2021123902A1 (fr) | 2019-12-20 | 2021-06-24 | Novartis Ag | Combinaison d'anticorps anti-tim-3 mbg453 et d'anticorps anti-tgf-bêta nis793, avec ou sans décitabine ou l'anticorps anti pd-1 spartalizumab, pour le traitement de la myélofibrose et du syndrome myélodysplasique |
| EP4125870A1 (fr) | 2020-03-30 | 2023-02-08 | Noxopharm Limited | Méthodes de traitement d'une inflammation associée à une infection |
| KR20210152312A (ko) * | 2020-06-08 | 2021-12-15 | 주식회사 종근당 | 카나비노이드 수용체 (cb1 수용체) 길항제로서의 4-(4,5-디하이드로-1h-피라졸-1-닐)피리미딘 화합물 및 이를 포함하는 약제학적 조성물 |
| MX2022015852A (es) | 2020-06-23 | 2023-01-24 | Novartis Ag | Regimen de dosificacion que comprende derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona. |
| US20230271940A1 (en) | 2020-08-03 | 2023-08-31 | Novartis Ag | Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| EP4240491A1 (fr) | 2020-11-06 | 2023-09-13 | Novartis AG | Molécules de liaison à cd19 et utilisations associées |
| US20240141060A1 (en) | 2021-01-29 | 2024-05-02 | Novartis Ag | Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof |
| TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途 |
| AR125874A1 (es) | 2021-05-18 | 2023-08-23 | Novartis Ag | Terapias de combinación |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6339875A (ja) | 1986-08-05 | 1988-02-20 | Nissin Food Prod Co Ltd | ピリミジン誘導体 |
| NZ517202A (en) * | 1999-08-24 | 2004-05-28 | Medarex Inc | Human CTLA-4 antibodies and their uses |
| US7605238B2 (en) * | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| JP2005516917A (ja) | 2001-12-12 | 2005-06-09 | アメリカ合衆国 | 細胞外アデノシン阻害剤およびアデノシン受容体阻害剤を用いて免疫応答および炎症を増強するための方法 |
| US20080058356A1 (en) | 2003-12-15 | 2008-03-06 | Neurocrine Biosciences, Inc. | 2,6 Bisheteroaryl-4-Aminopyrimidines as Adenosine Receptor Antagonists |
| US20080275064A1 (en) | 2005-04-11 | 2008-11-06 | Deborah Slee | Substituted Pyrimidines as Adenosine Receptor Antagonists |
| WO2008147482A2 (fr) * | 2007-02-13 | 2008-12-04 | Northeastern University | Procédés et compositions pour améliorer les réponses immunitaires |
| JP2010522214A (ja) | 2007-03-21 | 2010-07-01 | アルミラル， エセ．アー． | アデノシンレセプターアンタゴニストとしての置換ピリミジン |
| US9585957B2 (en) | 2007-09-07 | 2017-03-07 | The Johns Hopkins University | Adenosine receptor agonists and antagonists to modulate T cell responses |
| US8114845B2 (en) | 2008-08-25 | 2012-02-14 | Amplimmune, Inc. | Compositions of PD-1 antagonists and methods of use |
| CA2738252C (fr) * | 2008-09-26 | 2018-05-01 | Dana-Farber Cancer Institute, Inc. | Anticorps anti-pd-1, pd-l1, et pd-l2 humains et leurs utilisations |
| ES2365960B1 (es) * | 2010-03-31 | 2012-06-04 | Palobiofarma, S.L | Nuevos antagonistas de los receptores de adenosina. |
| KR20160079114A (ko) * | 2013-11-11 | 2016-07-05 | 아르모 바이오사이언시스 인코포레이티드 | 질환 및 장애를 치료하기 위한 인터류킨-10을 사용하는 방법 |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| CN108025051B (zh) * | 2015-07-29 | 2021-12-24 | 诺华股份有限公司 | 包含抗pd-1抗体分子的联合疗法 |
| SG10202111808WA (en) * | 2015-08-11 | 2021-11-29 | Novartis Ag | 5-bromo-2,6-di-(1h-pyrazol-1-yl)pyrimidin-4-amine for use in the treatment of cancer |
-
2016
- 2016-08-10 SG SG10202111808WA patent/SG10202111808WA/en unknown
- 2016-08-10 MX MX2018001721A patent/MX2018001721A/es active IP Right Grant
- 2016-08-10 KR KR1020187006576A patent/KR102114562B1/ko active IP Right Grant
- 2016-08-10 US US15/751,140 patent/US10561653B2/en active Active
- 2016-08-10 BR BR112018002585-2A patent/BR112018002585A2/pt not_active Application Discontinuation
- 2016-08-10 JP JP2018527029A patent/JP6663493B2/ja active Active
- 2016-08-10 CA CA2994918A patent/CA2994918C/fr active Active
- 2016-08-10 EP EP16766384.8A patent/EP3334431B9/fr active Active
- 2016-08-10 WO PCT/IB2016/054834 patent/WO2017025918A1/fr active Application Filing
- 2016-08-10 AU AU2016306090A patent/AU2016306090B2/en active Active
- 2016-08-10 RS RS20191573A patent/RS59688B1/sr unknown
- 2016-08-10 SI SI201630543T patent/SI3334431T1/sl unknown
- 2016-08-10 PL PL16766384T patent/PL3334431T3/pl unknown
- 2016-08-10 CN CN201680059231.7A patent/CN108348521B/zh active Active
- 2016-08-10 CN CN202111365426.3A patent/CN114129568A/zh active Pending
-
2018
- 2018-02-08 PH PH12018500284A patent/PH12018500284A1/en unknown
- 2018-02-11 SA SA518390901A patent/SA518390901B1/ar unknown
-
2019
- 2019-12-19 CY CY20191101337T patent/CY1122966T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL3334431T3 (pl) | 2020-03-31 |
| PH12018500284A1 (en) | 2018-08-13 |
| CN108348521B (zh) | 2021-12-03 |
| CY1122966T1 (el) | 2021-10-29 |
| SA518390901B1 (ar) | 2023-01-19 |
| KR102114562B1 (ko) | 2020-05-26 |
| US20180228802A1 (en) | 2018-08-16 |
| CN108348521A (zh) | 2018-07-31 |
| CA2994918A1 (fr) | 2017-02-16 |
| BR112018002585A2 (pt) | 2018-10-16 |
| AU2016306090B2 (en) | 2019-05-02 |
| EP3334431B1 (fr) | 2019-09-25 |
| KR20180048684A (ko) | 2018-05-10 |
| WO2017025918A1 (fr) | 2017-02-16 |
| CA2994918C (fr) | 2024-03-19 |
| RS59688B1 (sr) | 2020-01-31 |
| JP2018528264A (ja) | 2018-09-27 |
| CN114129568A (zh) | 2022-03-04 |
| EP3334431A1 (fr) | 2018-06-20 |
| MX2018001721A (es) | 2018-09-06 |
| US10561653B2 (en) | 2020-02-18 |
| JP6663493B2 (ja) | 2020-03-11 |
| AU2016306090A1 (en) | 2018-03-08 |
| EP3334431B9 (fr) | 2020-03-04 |
| SI3334431T1 (sl) | 2020-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG10202111808WA (en) | 5-bromo-2,6-di-(1h-pyrazol-1-yl)pyrimidin-4-amine for use in the treatment of cancer | |
| ZA201905902B (en) | 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer | |
| IL252053A0 (en) | Substituted pyrazolo(1,5-a)pyrimidines and their use in the treatment of medical disorders | |
| HK1256283A1 (zh) | 治療癌症有用的二氫咪唑並吡嗪酮衍生物 | |
| IL276733A (en) | Use of Aribolin in cancer treatment | |
| IL259996A (en) | Combinations for cancer treatment | |
| IL251905A0 (en) | Epilimod for use in the treatment of kidney cancer | |
| ZA201706402B (en) | C.novyi for the treatment of solid tumors in humans | |
| IL251903B (en) | Epilimod for use in the treatment of colon cancer | |
| PL3258931T3 (pl) | Zastosowanie kabazitakselu w leczeniu nowotworu złośliwego prostaty | |
| IL253933A0 (en) | History of pyrimidine use in the treatment of cancer | |
| IL257350A (en) | 5-bromo-2,6-di-(lh-pyrazol-l-yl)pyrimidin-4-amine for use in the treatment of cancer | |
| PT3580211T (pt) | 2-heteroaril-3-oxo-2,3-di-hidropiridazina-4-carboxamidas para o tratamento de cancro | |
| GB2553684B (en) | Ethynylxanthines, preparation and use for cancer treatment |